Biotechnology Acquisitions in United States

Sensei Biotherapeutics, Inc. acquired Faeth Therapeutics Inc., a clinical-stage biotechnology company developing multi-node cancer therapies, adding Faeth’s lead asset PIKTOR (serabelisib + sapanisertib) to Sensei’s oncology pipeline. Concurrent with the acquisition, Sensei entered into a $200 million private placement of Series B non-voting convertible preferred stock led by a syndicate of institutional life sciences investors to fund clinical development and general corporate purposes.

Swedish Orphan Biovitrum AB (publ) (Sobi) completed the acquisition of privately held Arthrosi Therapeutics, Inc., acquiring all outstanding shares of Arthrosi’s common stock and stock equivalents. The transaction expands Sobi’s gout franchise by adding pozdeutinurad (AR882), a once-daily oral URAT1 inhibitor in two fully enrolled global Phase 3 trials (REDUCE 1 and REDUCE 2) with data expected in 2026. Arthrosi is headquartered in San Diego, California, and rights to pozdeutinurad in Greater China are held by ApicHope.

Cycle Group Holdings Limited (Cycle Pharmaceuticals) completed the acquisition of NASDAQ-listed Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company. The deal is being funded from Cycle’s cash on hand and adds Applied’s lead CNS-penetrant drug candidate govorestat for rare metabolic diseases to the Cycle group.

Illumina has completed its acquisition of SomaLogic, adding data-driven proteomics capabilities to expand Illumina’s multiomics portfolio. Illumina acquired SomaLogic and certain other specified assets from Standard BioTools for $350 million in cash at closing (subject to customary adjustments), plus up to $75 million in near-term performance-based milestones and royalties.

Demeetra AgBio announced it has completed and fully integrated its acquisition of Hera BioLabs, with the transaction completed on June 1. Through the deal, Demeetra secured expanded rights to the hyperactive Super piggyBac transposase platform and consolidated commercial licensing and access under Demeetra.

Eclipse Bioinnovations, Inc. (Eclipsebio) acquired Terrain Bio to add AI/ML-driven RNA sequence design, active learning workflows, and mRNA manufacturing analytics to its sequencing-based analytics platform. The combination is intended to create an end-to-end “Design, Make, Test” workflow for RNA therapeutics spanning computational design, R&D-scale manufacturing, and sequencing-based validation and quality control. Eclipsebio will continue supporting existing Terrain Bio customers and manage a transition with partners.

Repare Therapeutics Inc. completed the acquisition of all issued and outstanding common shares by XenoTherapeutics, Inc. and Xeno Acquisition Corp. via a statutory plan of arrangement. Repare shareholders received approximately US$2.20 per share in cash (based on Repare’s cash balance net of liabilities and transaction costs) plus a non-transferable contingent value right (CVR) per share. Following closing, Repare expects its shares to cease trading on Nasdaq and to suspend and deregister its SEC reporting obligations.

Mirum Pharmaceuticals has completed its acquisition of Bluejay Therapeutics, adding Bluejay’s late-stage monoclonal antibody brelovitug for chronic hepatitis delta virus and expanding Mirum’s rare liver disease footprint. Mirum acquired all outstanding shares for a combination of cash and Mirum common stock, with potential additional tiered sales-based milestone payments. Following closing, Mirum plans to integrate Bluejay’s team and advance the global AZURE Phase 3 program toward potential regulatory filings and commercialization.

Zydus Lifesciences Limited completed a set of agreements with Agenus Inc. to acquire Agenus’ biologics manufacturing facilities and operations, following required regulatory approvals including CFIUS clearance. The acquired assets (in Emeryville and Berkeley, California) will be housed in a newly formed U.S. subsidiary, Zylidac Bio LLC, forming the foundation of Zydus’ U.S.-based biologics CDMO platform. As part of the broader transaction structure, Zydus also entered into exclusive licensing and manufacturing arrangements tied to Agenus’ Phase 3 immuno-oncology assets botensilimab and balstilimab, including commercialization rights in India and Sri Lanka.

AstraZeneca acquired Boston-based Modella AI, expanding a partnership formed under a multi-year agreement announced in July 2025. Modella AI’s multimodal foundation models and generative/agentic AI platform will be integrated into AstraZeneca’s global oncology R&D to accelerate clinical development, improve biomarker discovery, and automate data-intensive workflows. Financial terms were not disclosed.

Merck Sharp & Dohme (a subsidiary of Merck & Co., known as MSD outside the United States and Canada) completed its acquisition of Cidara Therapeutics via a cash tender offer followed by a merger, paying $221.50 per share in cash. The deal values the transaction at approximately $9.2 billion and brings Cidara’s long-acting antiviral candidate CD388 into Merck’s respiratory portfolio. Following closing on January 7, 2026, Cidara became a wholly owned subsidiary of Merck and its shares were delisted from Nasdaq.

Day One Biopharmaceuticals, Inc. has completed its acquisition of Mersana Therapeutics, Inc. via a tender offer and subsequent statutory merger, making Mersana a wholly owned subsidiary of Day One. Mersana shareholders received $25.00 per share in cash plus one non-tradable contingent value right (CVR) per share, providing for potential milestone payments of up to $30.25 per CVR (up to $55.25 per share total). The transaction expands Day One’s oncology pipeline with the clinical-stage antibody-drug conjugate emiltatug ledadotin (Emi‑Le) targeting adenoid cystic carcinoma.

Johnson & Johnson completed its acquisition of Halda Therapeutics OpCo, Inc., a clinical-stage biotechnology company, for $3.05 billion in cash. The deal brings Halda’s proprietary RIPTAC platform and its lead prostate-cancer asset HLD-0915, along with earlier-stage solid-tumor programs, into Johnson & Johnson’s oncology portfolio.

LifeNet Health has acquired Tissue Testing Technologies LLC (T3), a biotechnology company specializing in biopreservation technologies and services. The deal adds T3’s vitrification preservation and controlled warming capabilities to LifeNet Health’s regenerative medicine offering, aiming to extend organ and tissue viability for transplantation and clinical/research applications.

Natera completed the acquisition of Foresight Diagnostics in a deal valued at up to $450 million. The consideration includes an upfront all-stock component valued at $275 million plus up to $175 million tied to revenue and reimbursement milestones, expanding Natera’s capabilities in molecular residual disease testing across solid tumors and hematologic cancers.

Eli Lilly and Company completed its tender offer and acquisition of Adverum Biotechnologies through its wholly owned subsidiary, Flying Tigers Acquisition Corporation. Adverum shareholders received $3.56 per share in cash plus one non-tradable contingent value right (CVR) per share providing up to $8.91 in additional milestone-based payments; the tender offer was scheduled to be consummated on December 9, 2025.

Innova Therapeutics has completed the acquisition of Enci Therapeutics, adding Enci’s lead oncology program, IVT-8086, to Innova’s development pipeline. IVT-8086 is a first-in-class humanized monoclonal antibody targeting SFRP2 in the non-canonical Wnt/Ca2+ signaling pathway, with potential applications across multiple solid and hematologic cancers. Financial terms were not disclosed.

Pfizer Inc. completed its acquisition of Metsera, Inc., a clinical-stage biopharmaceutical company developing obesity and cardiometabolic disease therapies. Pfizer acquired all outstanding Metsera shares for $65.60 per share in cash (approximately $7.0 billion enterprise value) plus a contingent value right of up to $20.65 per share tied to clinical and regulatory milestones, and Metsera became a wholly owned subsidiary of Pfizer.

Axsome Therapeutics obtained exclusive global commercial, development, and manufacturing rights to the epilepsy candidate AZD7325, originally developed by AstraZeneca. Axsome secured the rights through acquiring 100% of Baergic Bio (an Avenue Therapeutics subsidiary) and amending Baergic Bio’s existing license agreement with AstraZeneca, with upfront and milestone payments plus royalties payable to Baergic Bio shareholders and to AstraZeneca.

Colossal Biosciences acquired Viagen Pets and Equine, a Texas-based animal cloning and genetic preservation company, to expand its de-extinction, conservation, and species preservation capabilities. Viagen will operate as a wholly owned subsidiary under its existing leadership, continuing to provide cloning, cryopreservation, and related reproductive technologies while scaling its endangered species work globally.

The Jackson Laboratory (JAX) announced the completion of its acquisition of the New York Stem Cell Foundation (NYSCF), combining JAX’s genetics and preclinical modeling expertise with NYSCF’s stem cell automation and high-throughput research capabilities. The combined nonprofit platform aims to accelerate early-stage biomedical discovery and translational medicine by integrating genomics, stem cell innovation, and AI-driven data science.

SERB Pharmaceuticals completed its acquisition of Y-mAbs Therapeutics, Inc., making Y-mAbs a wholly owned subsidiary of SERB. The transaction was executed via a tender offer at $8.60 per share followed by a statutory merger under Delaware law, and Y-mAbs was delisted from the Nasdaq Global Select Market.

Quintara Biosciences completed the acquisition of Laragen Sanger Sequencing, a business formerly operated by Transnetyx, effective September 15, 2025. The deal is intended to ensure uninterrupted Sanger sequencing services for Laragen’s existing Los Angeles customer base while expanding Quintara’s sequencing and molecular biology services footprint across California.

Bausch Health Companies Inc. completed its tender offer and subsequent merger to acquire DURECT Corporation, making DURECT a wholly owned subsidiary. Bausch Health paid $1.75 per share in cash (about $63 million upfront) and the deal also provides for up to $350 million in additional net sales milestone payments via CVRs. The acquisition adds DURECT’s lead asset larsucosterol, an FDA Breakthrough Therapy-designated candidate for alcohol-associated hepatitis, to Bausch Health’s hepatology pipeline.

PharmaCyte Biotech, Inc. increased its stake in TNF Pharmaceuticals by investing an additional $3 million. The investment is intended to support TNF’s recent acquisition of a technology license from LightSolver, Ltd. for a light-based processing accelerator aimed at compute-intensive applications, including cryptocurrency mining and blockchain.

Battery Ventures completed the take-private acquisition of Enzo Biochem, a life-science research reagents company. Battery intends to support Enzo’s next phase of innovation and growth through increased R&D investment, operational initiatives, and targeted acquisitions, with Jason Apter joining as group CEO.

Olaplex Holdings, Inc. announced it has acquired Purvala Bioscience, a Boston-based biotech company founded by Dr. Bradley Olsen. The deal represents OLAPLEX’s first acquisition since its launch and is intended to support next-generation, science-backed innovation in haircare and broader health and beauty applications.

AbbVie completed its acquisition of Capstan Therapeutics, making Capstan part of AbbVie. The deal adds Capstan’s lead asset CPTX2309, a Phase 1 in vivo targeted lipid nanoparticle (tLNP) anti-CD19 CAR-T candidate for B cell-mediated autoimmune diseases, and Capstan’s proprietary tLNP platform for delivering RNA payloads to engineer specific cell types in vivo.

Vyome Therapeutics, Inc. closed its previously announced merger transaction with ReShape Lifesciences Inc. Following the closing, the combined company will operate as Vyome Holdings, Inc. and is expected to begin trading on Nasdaq under the ticker “HIND” on August 15, 2025.

Intas Pharmaceuticals, through its U.S. specialty subsidiary Accord BioPharma, completed the acquisition of the UDENYCA (pegfilgrastim-cbqv) franchise from Coherus BioSciences. The deal expands Intas/Accord’s FDA-approved biosimilar portfolio and strengthens its pegfilgrastim position in the U.S. and globally, with Accord continuing UDENYCA commercialization and integrating certain former Coherus employees to support transition and continuity.

Eli Lilly and Company announced it has successfully completed its acquisition of Verve Therapeutics, Inc. Verve is a Boston-based clinical-stage company developing genetic medicines, including gene-editing programs, for cardiovascular disease. Lilly said the deal supports development of one-time treatments aimed at lifelong cardiovascular risk reduction for patients with high cardiovascular risk.

Funds managed by Perceptive Advisors acquired substantially all assets of Synthego, a Redwood City, California-based provider of CRISPR solutions. The transaction closed on July 18, 2025, and Synthego will continue operating under its existing brand and leadership team.

TandemAI and Perpetual Medicines have merged, with the combined company operating under the TandemAI name to expand capabilities across physics- and AI-based drug discovery for both small molecules and peptides. TandemAI co-founder and CEO Jeff He will lead the combined company, while Perpetual Medicines will continue as a separate operating entity within TandemAI led by its existing leadership team. Financial terms were not disclosed.

Merck KGaA (Darmstadt, Germany) has completed its acquisition of SpringWorks Therapeutics, Inc. for an enterprise value of $3.4 billion (about €3 billion), following regulatory clearances. Merck becomes the sole owner and SpringWorks shares will no longer trade on Nasdaq, with SpringWorks shareholders receiving $47 per share in cash. The deal adds SpringWorks’ rare tumor portfolio (including Ogsiveo and Gomekli) to accelerate Merck’s Healthcare growth and expand its rare tumor business.

TuHURA Biosciences, Inc. completed its acquisition of Kineta, Inc., adding Kineta’s VISTA-inhibiting monoclonal antibody program (formerly KVA1213/KVA12123, now renamed TBS-2025) to TuHURA’s immuno-oncology pipeline. Under the merger agreement, Kineta shareholders received TuHURA stock (plus additional contingent shares and potential cash from legacy asset dispositions), and the closing also unlocked the fourth tranche of TuHURA’s previously announced $12.5 million PIPE financing.

Novartis completed its acquisition of Regulus Therapeutics Inc., and Regulus became an indirect wholly owned subsidiary of Novartis with its shares ceasing trading on Nasdaq. The transaction was executed via a tender offer and subsequent merger through Novartis’ indirect subsidiary Redwood Merger Sub Inc., with consideration of $7.00 per share in cash plus one contingent value right (CVR) per share tied to a regulatory milestone.

Juvenescence Limited announced the acquisition of Ro5 Inc., a proprietary AI drug discovery company, to enhance its AI/ML-enabled drug discovery and R&D capabilities. Ro5’s Biomedical Knowledge Graph and AI Chemistry Platform will be integrated into Juvenescence to accelerate development of therapeutics targeting age-related diseases, and the deal supports Juvenescence’s strategic partnership with M42.

Continuity Biosciences, LLC acquired Focal Medical, Inc., a North Carolina-based biopharmaceutical company developing iontophoresis-based, site-specific chemotherapy delivery for solid tumors including pancreatic cancer. The deal adds Focal Medical’s patent estate, technology platform and equipment, R&D facility in Cary, North Carolina, and certain licensing agreements (including with the University of North Carolina at Chapel Hill) to Continuity’s drug-delivery portfolio.

Sun Pharmaceutical Industries Limited (Sun Pharma) announced it has successfully completed the acquisition of Checkpoint Therapeutics, Inc., an immunotherapy and targeted oncology company. Sun Pharma acquired all outstanding Checkpoint shares for $4.10 per share in cash plus a non-tradable contingent value right (CVR) of up to an additional $0.70 per share tied to milestone achievement. The deal also adds Checkpoint’s FDA-approved anti-PD-L1 therapy UNLOXCYT to Sun Pharma’s oncology-dermatology portfolio.

Altos Labs has acquired Dorian Therapeutics, a Stanford University spinout developing small-molecule senescence-targeting therapeutics ("senoblockers") in the cellular rejuvenation and longevity space. Financial terms were not disclosed, and the combination is positioned to pair Altos’ cellular rejuvenation programming efforts with Dorian’s senescence-modulating approach and preclinical pipeline.

BioMarin Pharmaceutical Inc. completed its acquisition of Inozyme Pharma, Inc. in an all-cash transaction valued at approximately $270 million, paying $4.00 per share. The deal was executed via a tender offer followed by a merger of BioMarin’s wholly owned subsidiary, Incline Merger Sub, Inc., into Inozyme, with remaining shares converted to the same $4.00 per share cash consideration. The acquisition adds INZ-701, a late-stage (Phase 3) enzyme replacement therapy in development for ENPP1 Deficiency, strengthening BioMarin’s enzyme therapies portfolio.

bluebird bio entered into, and subsequently completed, an acquisition by funds managed by Carlyle and SK Capital Partners via a tender offer and merger, taking the company private. Stockholders received either $3.00 per share in cash plus a contingent value right (CVR) for up to $6.84 per share upon achievement of a $600 million net sales milestone by December 31, 2027, or alternatively $5.00 per share in cash with no CVR after the merger agreement was amended. The transaction closed on June 2, 2025, with Carlyle and SK Capital committing significant primary capital to support scaling bluebird’s commercial gene therapy delivery.

Gedeon Richter Plc. made a strategic investment in Granata Bio, acquiring a significant equity stake and gaining a board representative as part of a broader collaboration to expand women’s health and fertility offerings in the United States. Alongside the equity investment, the parties signed agreements covering co-development of Richter’s BEMFOLA for the U.S. market and a royalty purchase arrangement related to Granata’s proprietary hMG program.

GeneDx announced it has completed its acquisition of Fabric Genomics, an AI-powered genomic interpretation company. Fabric Genomics will operate as an independent subsidiary, and the combined capabilities are intended to expand end-to-end genomic diagnostics offerings, including NICU testing, genomic newborn screening, and global AI interpretation services.

CellBio Scientific announced it has acquired BioChain, a provider of biospecimen collection, preparation, and analysis, to expand its life science tools and translational research platform. BioChain will remain headquartered in Newark, California, with its leadership team continuing to run local operations and the BioChain CEO reporting to CellBio Scientific CEO Charles Miller.

Synhale Therapeutics Inc., a virtual clinical-stage biotech company focused on pulmonary hypertension (PH), announced that it has acquired Telaglenastat (CB-839), a first-in-class glutaminase inhibitor. Synhale plans to advance Telaglenastat into a Phase 2 clinical program across PH Groups 1–4 and indicated it is initiating a new fundraising round to support development.

Granata Bio announced the acquisition of Oviva Therapeutics, a women’s health biotech company focused on treatments addressing female physiology with an emphasis on ovarian aging. Oviva’s lead candidate, OVI-586, is a first-in-class therapeutic aimed at extending ovarian function with potential applications across menopause, contraception, and IVF. Cambrian BioPharma, which partnered to found Oviva, highlighted the transaction as advancing novel women’s health innovation under Granata’s leadership.

BioLife Solutions, Inc. acquired privately held PanTHERA CryoSolutions, Inc., a developer of cryopreservation solutions based on proprietary Ice Recrystallization Inhibitor (IRI) technology. BioLife purchased the 90% of PanTHERA common shares it did not already own for $9.3 million in cash and 241,355 shares of BioLife common stock, with PanTHERA shareholders eligible to receive up to an additional $7.2 million in BioLife stock tied to milestones.

Epsilogen has completed the acquisition of TigaTx, Inc., combining Epsilogen’s IgE antibody capabilities with TigaTx’s engineered IgA antibody platform to form a pan-isotype cancer antibody company. Following the transaction, Boston-based TigaTx becomes a wholly owned subsidiary of Epsilogen; financial terms were not disclosed. As part of the announcement, Dr. Sonia Gulati of Global BioAccess Fund joined Epsilogen’s board of directors.

Artis BioSolutions, a newly launched genetic medicines-focused CDMO backed by Oak HC/FT, announced the acquisition of Landmark Bio. Landmark Bio will continue operating as a distinct entity from its headquarters in Watertown, Massachusetts, scaling capabilities across translational research, process development, and GMP manufacturing to support advanced cell and gene therapies from preclinical development through commercialization.

Alcon acquired a majority interest in Aurion Biotech, Inc., a clinical-stage company developing allogeneic cell therapies for eye diseases. Aurion will continue to operate as a separate company with Alcon’s support to advance its lead asset AURN001 into U.S. Phase 3 development for corneal edema secondary to corneal endothelial disease in the second half of 2025.

Sanofi and Dren Bio, Inc. entered into a definitive agreement for Sanofi to acquire DR-0201, a CD20-directed bispecific myeloid cell engager, via the acquisition of Dren Bio’s affiliate Dren-0201. Sanofi will pay $600 million upfront plus up to $1.3 billion in potential milestone payments, while Dren Bio will continue operating independently after the transaction. The deal is expected to close in Q2 2025, subject to customary closing conditions and regulatory approvals.

FairJourney Biologics S.A. has completed the acquisition of Charles River Laboratories International, Inc.’s South San Francisco facility (formerly Distributed Bio). The deal transfers ownership of the site’s facilities, staff, assets, and proprietary antibody discovery technologies—including the SuperHuman, Cosmic and Tungsten libraries and Charles River’s Yeast Display method—expanding FairJourney’s antibody discovery and engineering capabilities in a major US biotech hub.

Dxcover, a University of Strathclyde spin-out focused on early cancer detection, raised £5 million in a funding round. New investors included the Investment Fund for Scotland (IFS) (managed by Maven and delivered by the British Business Bank) and Macmillan Cancer Support, alongside existing investors Eos Advisory (lead), SIS Ventures, the University of Strathclyde, and Norcliffe Capital. The funding will support technology development, commercial expansion, and market entry across the United Kingdom, Europe, and the United States, with headquarters being established in Nashville, Tennessee.

Novartis has agreed to acquire, and subsequently completed the acquisition of, Anthos Therapeutics, a clinical-stage biopharmaceutical company developing abelacimab, a Factor XI inhibitor for atrial fibrillation and cancer-associated thrombosis. The transaction is valued at up to $3.1 billion, consisting of $925 million paid upfront to Anthos shareholders plus additional potential regulatory and commercial milestone payments.

Tidal Vision announced the close of an oversubscribed $140 million Series B financing to scale its chitosan-based chemistries globally. Cambridge Companies SPG led the round, which also included Eni Next, Milliken & Company, KIRKBI Climate, Convent Capital, SWEN Capital Partners' Blue Ocean Fund, MBX Capital, and Oman Investment Authority's IDO Investments. Proceeds will support expanded production capacity and R&D, including new infrastructure in Europe, Texas, and Ohio.

VION Biosciences acquired BioAssay Systems in January 2025 as the fourth acquisition under the VION life science platform. BioAssay Systems develops high-throughput biochemical and enzyme-mediated assay solutions for life science research and drug discovery and will continue operating from Hayward, California under CEO Frank Huang as a VION subsidiary.

AbbVie completed its acquisition of Nimble Therapeutics, making Nimble part of AbbVie. The deal adds Nimble’s investigational oral peptide IL23R inhibitor program for psoriasis (preclinical) and its proprietary peptide synthesis, screening and optimization platform to strengthen AbbVie’s immunology pipeline and R&D discovery capabilities.

EmergentMedTech announced a merger with TRU Biologix to expand its portfolio of biologics and regenerative medicine offerings. With TRU Biologix joining the EmergentMedTech family, the combined company will provide cell and tissue products (including Wharton’s Jelly-derived solutions) alongside other regenerative technologies for clinics, researchers, and clinicians.

Bausch + Lomb Corporation announced that an affiliate has acquired Whitecap Biosciences, LLC, a clinical-stage company developing therapies for glaucoma and geographic atrophy (GA). Whitecap’s pipeline includes WB007 (a highly potent alpha-2 adrenergic agonist) that has completed Phase 2 clinical trials in glaucoma, with additional trials planned for glaucoma and GA. The acquisition is intended to strengthen Bausch + Lomb’s clinical-stage ophthalmology pipeline.

Marijuana, Inc. (dba Exousia Pro, Inc.) acquired 100% of Exousia AI in a cash-and-stock transaction from Ludwig Enterprises, Inc. As consideration, Exousia Pro will issue 47,000,000 restricted common shares, assume liabilities under $75,000, and provide a $100,000 note. The deal adds exosome-related biotechnology IP and ongoing studies, supporting Exousia Pro’s expansion into dermatology, nutraceutical, and other therapeutic applications.

VBI Vaccines Inc. completed a sales process and transaction under Canadian CCAA creditor protection proceedings with K2 VBI Equity Trust, LLC, an affiliate of K2 HealthVentures LLC. Following closing, VBI’s outstanding common shares were redeemed and cancelled, and VBI and certain subsidiaries became wholly owned by the purchaser and emerged from the CCAA proceedings.

Altaris, LLC entered into a definitive agreement to acquire, and subsequently completed the acquisition of, WuXi AppTec’s Advanced Therapies Unit U.S. and U.K. operations, including OXGENE, with closing occurring on 7 March 2025. Following the transaction, Advanced Therapies is fully owned by Altaris and headquartered in the United States, and Altaris plans to combine Advanced Therapies with its Minaris Regenerative Medicine platform into a single company, Minaris Advanced Therapies, in the first half of 2025.

Novo Holdings A/S completed its all-cash acquisition of Catalent, Inc. for approximately $16.5 billion in enterprise value, with Catalent shareholders receiving $63.50 per share. Following closing, Catalent will operate as a private company under Novo Holdings’ ownership. Novo Nordisk A/S is expected to acquire from Novo Holdings three Catalent fill-finish sites in Anagni (Italy), Bloomington, Indiana (USA), and Brussels (Belgium) and related assets shortly after the merger closes.

AbbVie has completed its $1.4 billion acquisition of Aliada Therapeutics, adding Aliada’s lead investigational Alzheimer’s candidate ALIA-1758 and its blood-brain barrier-crossing drug delivery technology to AbbVie’s neuroscience pipeline. Aliada was co-founded in 2021 by RA Capital Management/Raven and Johnson & Johnson (via JJDC), based on the MODEL platform created by Johnson & Johnson scientists and licensed to Aliada at inception.

Chroma Medicine and Nvelop Therapeutics merged and launched a combined company, nChroma Bio, to unite epigenetic editing and next-generation in vivo delivery technologies for genetic medicines. Concurrent with the merger, nChroma Bio closed an oversubscribed $75 million financing round led by Cormorant Asset Management, ARCH Venture Partners, Atlas Venture, and Newpath Partners to advance its lead program CRMA-1001 and expand its pipeline.

Ampersand Capital Partners completed the acquisition of Nektar Therapeutics' PEGylation (polyethylene glycol) reagent manufacturing business. The acquired business was launched as a new Ampersand portfolio company branded Gannet BioChem, operating from its Huntsville, Alabama GMP manufacturing facility and serving biopharmaceutical customers with PEG reagent CDMO capabilities.

Roche Holdings, Inc. entered into a merger agreement to acquire Poseida Therapeutics, Inc. via a tender offer followed by a second-step merger. Poseida shareholders will receive $9.00 per share in cash at closing plus a non-tradeable contingent value right (CVR) for up to $4.00 per share upon achievement of milestones, for a total equity value of up to approximately $1.5 billion. Poseida (based in San Diego) will join the Roche Group’s Pharmaceuticals Division, strengthening Roche’s capabilities in allogeneic cell therapy and CAR-T programs across oncology and autoimmune disease.

Abpro Corporation and special purpose acquisition company Atlantic Coastal Acquisition Corp. II completed their previously announced business combination, creating Abpro Holdings, Inc., with Abpro Corporation becoming a wholly owned subsidiary. Abpro Holdings is expected to begin trading on Nasdaq under the tickers ABP (common stock) and ABPWW (warrants) on November 14, 2024. In connection with the transaction, Celltrion purchased $5 million of Abpro common stock in a PIPE financing and gained board representation.

ARCHIMED, a healthcare-focused private equity firm, acquired SeqCenter, a Pittsburgh, Pennsylvania-based provider of DNA and RNA next-generation sequencing (NGS) services. The investment was made through ARCHIMED’s MED Rise fund and is intended to accelerate SeqCenter’s international expansion in Europe and Asia and support development of more advanced sequencing technologies.

Lomond Therapeutics, Inc. completed a reverse merger with Venetian-1 Acquisition Corp., which subsequently changed its name to Lomond Therapeutics Holdings, Inc. Concurrently, the company closed a $44 million private placement financing with participation from existing investors and new investors led by Deerfield Management Company, alongside American Financial Group and Heights Capital.

Quris-AI announced the successful asset acquisition of Nortis, recently known as Numa Biosciences, Inc. Quris-AI plans to integrate Nortis’s Kidney-on-Chip microphysiology technology into its Bio-AI clinical prediction platform to improve drug safety prediction and support further research collaborations.

INVO Bioscience (Nasdaq: INVO) closed its merger with NAYA Biosciences, acquiring 100% of NAYA through a reverse triangular merger and making NAYA a wholly owned subsidiary. Consideration to NAYA securityholders consisted of INVO common stock and Series C-1 and Series C-2 preferred stock, and the combined company changed its corporate name to NAYA Biosciences Inc. and began trading under the ticker “NAYA.”

Vizgen, Inc. and Ultivue, Inc. announced a merger to combine Vizgen’s single-cell spatial genomics capabilities with Ultivue’s multiplex proteomic profiling and AI-driven spatial tissue profiling, creating a unified spatial multi-omics organization. Concurrent with the merger, Vizgen completed a Series D equity financing round backed by investors including ARCH Venture Partners, Northpond Ventures and Tao Capital Partners. Rob Carson (formerly Ultivue CEO) will lead the combined company as President and CEO of the newly combined Vizgen.

SK bioscience agreed to acquire a stake in U.S.-based Fina Biosolutions (FinaBio) through a USD 3 million investment, becoming FinaBio’s first and sole strategic investor. The partnership is intended to enhance the immunogenicity and productivity of conjugate vaccines by leveraging FinaBio’s CRM197 (EcoCRM) carrier protein and site-specific conjugation technology.

Cellipont Bioservices, a cell therapy contract development and manufacturing organization (CDMO) headquartered in The Woodlands, Texas, received a minority growth equity investment from HealthQuest Capital. Great Point Partners (GPP), Cellipont’s majority investor, also participated in the financing, which supports Cellipont’s continued expansion of cell-therapy development and manufacturing capabilities.

Calibre Scientific has acquired Molecular Research Center, Inc. (MRC), a US-based manufacturer specializing in RNA isolation technologies. Founded in 1989 and headquartered in Ohio, MRC develops and manufactures reagents and kits used for RNA and DNA isolation and analysis across molecular biology, biotechnology, and genetic research.

Molecular Designs acquired Lamda Biotech, a provider of research products used in molecular biology, functional genomics, proteomics and gene therapy. The deal is intended to expand Molecular Designs’ PCR product portfolio, increase R&D and manufacturing scale, and broaden distribution into academic research and pharma customer segments.

Altaris, LLC agreed to acquire and subsequently completed the acquisition of Minaris Regenerative Medicine from Resonac Corporation (a subsidiary of Resonac Holdings Corporation). Minaris is a cell therapy contract development and manufacturing organization (CDMO) serving pharmaceutical and biotech customers globally, and will operate as a wholly owned portfolio company of Altaris, headquartered in the United States.

Leinco Technologies, backed by Ampersand Capital Partners, acquired Genovis-owned QED Biosciences, a provider of antibodies, kits, recombinant proteins and antigens for IVD and research markets. The deal expands Leinco’s antibody product portfolio and complements its antibody development and related services for global research and diagnostics customers.

VION Biosciences, a life science platform backed by Iron Path Capital, acquired Ansh Labs, a Houston-based biotechnology company focused on immunoassay kits and reagents for research and clinical diagnostics. The acquisition expands VION’s capabilities into contract development and custom manufacturing of novel immunoassays and specialty reagents, adding GMP manufacturing for IVD and ISO 13485-certified capabilities.

VION Biosciences, a life science specialty reagents platform backed by Iron Path Capital, acquired Echelon Biosciences, a Salt Lake City-based supplier of specialty lipids, lipid-based excipients, and lipid nanoparticles. The deal expands VION’s capabilities from drug discovery and pre-clinical development into drug manufacturing, building on VION’s prior Aldon acquisition in 2023. Echelon will operate as a subsidiary of VION with its technical and commercial leadership remaining in place.

BioIVT, a biospecimen solutions provider for drug and diagnostic development, has acquired ZenBio Inc., a provider of advanced cell products and services. The deal expands BioIVT’s portfolio in skin-based expertise, primary cell and exosome isolation, and related biospecimen offerings serving pharmaceutical and cosmetics companies. Financial terms were not disclosed.

Energy Fuels Inc. acquired RadTran LLC on August 16, 2024 to expand its planned capabilities for developing and producing medical radioisotopes used in emerging cancer treatments. RadTran brings intellectual property and expertise in separating and concentrating radium-226 and radium-228 from uranium and thorium process streams, supporting potential future commercial production at Energy Fuels’ White Mesa Mill in Utah.

Citius Pharmaceuticals completed the previously announced merger of its oncology subsidiary with TenX Keane Acquisition, a publicly traded SPAC. The combined company was renamed Citius Oncology, Inc., is expected to trade on Nasdaq under the ticker “CTOR” starting August 13, 2024, and Citius Pharmaceuticals will hold approximately 90% of the newly public company.

Crown Laboratories, Inc., a Hildred Capital portfolio company, acquired Revance Therapeutics, Inc. via a cash tender offer followed by a second-step merger, resulting in Revance becoming wholly owned by Crown and being delisted from Nasdaq. The deal terms were revised during the process, with the final tender offer price set at $3.65 per share (after an amended agreement initially set $3.10 per share), superseding the original $6.66 per share announcement.

Pharmacosmos A/S, through its U.S. subsidiary Pharmacosmos Therapeutics Inc., entered into a definitive merger agreement to acquire all outstanding shares of G1 Therapeutics, Inc. in an all-cash transaction. G1 shareholders will receive $7.15 per share, valuing the equity at approximately $405 million, with closing expected late in the third quarter of 2024.

Boehringer Ingelheim acquired Nerio Therapeutics Inc., a San Diego-based drug discovery and development company focused on phosphatase targets, to add an innovative preclinical program to its immuno-oncology portfolio. The deal value was described as up to $1.3 billion. Nerio had been invested in and incubated by Viva BioInnovator (Viva Biotech) and developed in the Avalon BioVentures accelerator, with additional support from a syndicate of investors.

Otsuka Pharmaceutical Co., Ltd. entered into a definitive merger agreement to acquire Jnana Therapeutics Inc., which will become a wholly owned subsidiary via Otsuka America, Inc. Otsuka will pay $800 million in cash at closing plus up to $325 million in development and regulatory milestones. The deal adds Jnana’s RAPID chemoproteomics drug-discovery platform and lead PKU candidate JNT-517 to Otsuka’s specialty and autoimmune R&D portfolio.

Invetx Inc., a Boston, Massachusetts-based developer of protein-based veterinary therapeutics and monoclonal antibody candidates for cats and dogs, has agreed to be acquired by Dechra Pharmaceuticals Limited for up to $520 million in total consideration on a cash-free, debt-free basis. The transaction is subject to antitrust approval and other customary closing conditions and is expected to expand Dechra’s companion animal specialty therapeutics pipeline and access to Invetx’s half-life extension technology platform.

Lantheus Holdings, Inc. acquired Meilleur Technologies, Inc., including the NAV-4694 (F18-flutafuranol) β-amyloid PET imaging agent in Phase 3 development for Alzheimer’s disease. The deal grants Lantheus worldwide exclusive rights to NAV-4694 and expands its Alzheimer’s diagnostic pipeline, alongside its tau PET candidate MK-6240. The transaction was structured as a stock purchase with upfront payment, potential milestones, and royalties, and includes transition and clinical development services from the sellers post-close.

Illumina, Inc. acquired Fluent BioSciences on July 9, 2024, adding Fluent’s scalable single-cell analysis technology to expand Illumina’s multiomics capabilities. The transaction was funded with Illumina’s cash on hand, and Fluent’s team and PIPseq V product will be integrated into Illumina’s product portfolio.

Eli Lilly and Company entered into a definitive agreement to acquire Morphic Holding, a biopharmaceutical company developing oral integrin therapies, including MORF-057 for inflammatory bowel disease. Lilly offered $57 per share in cash (approximately $3.2 billion) via a tender offer followed by a second-step merger; the offer expired Aug. 15, 2024 with about 92.8% of shares tendered. Lilly completed the acquisition on Aug. 16, 2024 and Morphic’s shares were delisted from the Nasdaq Global Market.

AbbVie acquired Celsius Therapeutics, a privately held clinical-stage biotechnology company developing inflammatory disease therapies, for $250 million in cash (subject to customary adjustments). The deal provides AbbVie with Celsius’ lead investigational asset, CEL383, a potential first-in-class anti‑TREM1 antibody that has completed a Phase 1 study and is being developed for inflammatory bowel disease (IBD).

Primrose Bio, Inc. announced a significant equity investment from 1315 Capital to support development and commercial expansion of its biomanufacturing technology offerings for nucleic acids and proteins used in therapeutics and vaccines. The growth equity funding will help Primrose advance and scale platforms including Prima RNApols, Pfenex Expression Technology, and PeliCRM.

Ono Pharmaceutical Co. Ltd. completed its tender offer to acquire all outstanding shares of Deciphera Pharmaceuticals Inc. for $25.60 per share, valuing the deal at approximately $2.4 billion. The acquisition was executed through Ono’s wholly owned subsidiary, Topaz Merger Sub Inc., which merged into Deciphera, leaving Deciphera as the surviving entity and a wholly owned subsidiary of Ono.

GSK plc has acquired Elsie Biotechnologies, a private biotechnology company based in San Diego, for up to $50 million. The deal brings Elsie’s oligonucleotide discovery, synthesis, and delivery technologies into GSK to accelerate its next-generation oligonucleotide platform and pipeline medicines. The acquisition has been completed and was not subject to closing conditions.

AbbVie completed its acquisition of Landos Biopharma, a clinical-stage biopharmaceutical company developing novel oral therapeutics for autoimmune diseases. AbbVie paid $20.42 per share in cash plus one non-tradable contingent value right (CVR) per share worth up to $11.14 upon achievement of a clinical development milestone, adding Landos’ lead investigational asset NX-13 (in Phase 2 for ulcerative colitis) to its pipeline.

Orna Therapeutics announced the acquisition of ReNAgade Therapeutics to strengthen its leadership in circular RNA therapeutics and expand delivery and gene-editing capabilities. Following the deal, ReNAgade CEO Amit D. Munshi will become Chief Executive Officer of Orna, while Tom Barnes, Ph.D., will remain on Orna’s Board and serve as chair of its Scientific Advisory Board.

Biogen Inc. entered into a definitive agreement to acquire Human Immunology Biosciences (HI-Bio), a clinical-stage biotechnology company focused on immune-mediated diseases. The deal values HI-Bio at $1.15 billion upfront plus up to $650 million in potential milestone payments (up to $1.8 billion total), adding HI-Bio’s lead asset felzartamab and broader immunology pipeline to Biogen.